Skip to content Skip to footer
Subscribe Now
INSIGHTS+

Know Your Investor: Samsara Biocapital (November’25 Edition)  

Shots:  Samsara Biocapital is a California-based venture capital and registered investment adviser investing across early to post-IPO stages in healthcare, life sciences, oncology, and digital health, with a portfolio of 70+ companies including Scholar Rock and PepGen  The firm made 30 investments across PIPE (43%), Series B (23%), and other rounds, with notable deals such…
November 5, 2025

Read more

VIEWPOINTS_Dr. Jay Backstrom_2023
VIEWPOINTS

Dr. Jay Backstrom shares insights from the Phase II TOPAZ trial for the treatment of SMA

Shots:  Dr. Jay Backstrom in an engaging conversation with PharmaShots, shares the highlights of the P-II Topaz trial designed to evaluate the safety and efficacy of apitegromab for the treatment of Spinal Muscle Atrophy (Type 2 & 3)   With the potential to transform care in SMA by directly addressing progressive muscle weakness, apitegromab aims to…
November 7, 2023

Read more

Exclusive_Nagesh Mahanthappa_2022
EXCLUSIVE

Nagesh Mahanthappa, Interim CEO of Scholar Rock Shares Insights on Treatment Options for Spinal Muscular Atrophy

Shots: Nagesh talked about how Spinal Muscular Atrophy (SMA) is affecting people all over the world and how Scholar Rock’s treatment options are improving the lives of those living with this disease Nagesh also spoke about Scholar Rock’s lead product in SMA, apitegromab, highlighting its trial designs (TOPAZ & SAPPHIRE trials), outcomes, and real-world data…
October 3, 2022

Read more